Clinical trials of advanced melanoma have shown that the combining nivolumab with relatlimab, the first approved LAG‐3 mAb, can improve PFS and OS compared with nivolumab alone, and nivolumab plus relatlimab is safer than nivolumab plus ipilimumab.176, 177. This evidence concerns the gene LAG3 and melanoma.